Active	Status	Sponsor type	Region	Phase	Filter
11 Active 0 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Guojun
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer	Recruiting	3	450	RoW	camrelizumab + famitinib, pembrolizumab, camrelizumab	Jiangsu HengRui Medicine Co., Ltd.	Non-small Cell Lung Cancer	12/23	12/25
NIR, NCT05708144: Fluorescent Molecular Probe for the Identification of Breast Tissue	Completed	N/A	26	RoW	ICG-SG incubation solution	Xiang'an Hospital of Xiamen University	Breast Cancer	10/23	10/23
NCT06735118: Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver	Recruiting	N/A	120	RoW	Neoadjuvant chemotherapy, Non	Yunnan Cancer Hospital	Non-Alcoholic Fatty Liver Disease	12/24	12/24
NIR-II, NCT06713681: Trop2-targeting Molecular Probe for Breast Cancer Precise Surgery	Recruiting	N/A	40	RoW	TTP-ICG incubation solution	Yunnan Cancer Hospital, Affiliated Cancer Hospital of Shantou University Medical College	Breast Cancer, Sentinel Lymph Node, Margins of Excision	05/25	12/25
NIR-II, NCT06713161: Tumor-Targeted- Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status	Recruiting	N/A	40	RoW	NIR-II Probe(i.e ICG-POL6326) incubation solution	Yunnan Cancer Hospital, Xiang'an Hospital of Xiamen University	Breast Cancer, Sentinel Lymph Node, Metastases, Margin Assessment	08/25	12/25
NCT06742021: Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer	Recruiting	N/A	195	RoW	Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer	Yunnan Cancer Hospital	Lung Cancer	07/26	07/26
NCT06755866: DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer	Recruiting	N/A	135	RoW	The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer	Yunnan Cancer Hospital	Esophageal Cancer	07/26	07/26
NCT04076111: Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China	Not yet recruiting	N/A	20000	RoW		Fengxi Su	Breast Cancer	12/25	12/25
Fan, Xueqi
NCT05623280: Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node.	Recruiting	N/A	40	RoW	Indocyanine green, ICG	Xiang'an Hospital of Xiamen University	Breast Cancer, Sentinel Lymph Node	12/24	12/24
Chen, Weiling
NIR, NCT05708144: Fluorescent Molecular Probe for the Identification of Breast Tissue	Completed	N/A	26	RoW	ICG-SG incubation solution	Xiang'an Hospital of Xiamen University	Breast Cancer	10/23	10/23
NIR-II, NCT06713161: Tumor-Targeted- Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status	Recruiting	N/A	40	RoW	NIR-II Probe(i.e ICG-POL6326) incubation solution	Yunnan Cancer Hospital, Xiang'an Hospital of Xiamen University	Breast Cancer, Sentinel Lymph Node, Metastases, Margin Assessment	08/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Guojun
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer	Recruiting	3	450	RoW	camrelizumab + famitinib, pembrolizumab, camrelizumab	Jiangsu HengRui Medicine Co., Ltd.	Non-small Cell Lung Cancer	12/23	12/25
NIR, NCT05708144: Fluorescent Molecular Probe for the Identification of Breast Tissue	Completed	N/A	26	RoW	ICG-SG incubation solution	Xiang'an Hospital of Xiamen University	Breast Cancer	10/23	10/23
NCT06735118: Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver	Recruiting	N/A	120	RoW	Neoadjuvant chemotherapy, Non	Yunnan Cancer Hospital	Non-Alcoholic Fatty Liver Disease	12/24	12/24
NIR-II, NCT06713681: Trop2-targeting Molecular Probe for Breast Cancer Precise Surgery	Recruiting	N/A	40	RoW	TTP-ICG incubation solution	Yunnan Cancer Hospital, Affiliated Cancer Hospital of Shantou University Medical College	Breast Cancer, Sentinel Lymph Node, Margins of Excision	05/25	12/25
NIR-II, NCT06713161: Tumor-Targeted- Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status	Recruiting	N/A	40	RoW	NIR-II Probe(i.e ICG-POL6326) incubation solution	Yunnan Cancer Hospital, Xiang'an Hospital of Xiamen University	Breast Cancer, Sentinel Lymph Node, Metastases, Margin Assessment	08/25	12/25
NCT06742021: Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer	Recruiting	N/A	195	RoW	Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer	Yunnan Cancer Hospital	Lung Cancer	07/26	07/26
NCT06755866: DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer	Recruiting	N/A	135	RoW	The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer	Yunnan Cancer Hospital	Esophageal Cancer	07/26	07/26
NCT04076111: Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China	Not yet recruiting	N/A	20000	RoW		Fengxi Su	Breast Cancer	12/25	12/25
Fan, Xueqi
NCT05623280: Artificial Intelligence Analysis of Fluorescence Image to Intraoperatively Detect Metastatic Sentinel Lymph Node.	Recruiting	N/A	40	RoW	Indocyanine green, ICG	Xiang'an Hospital of Xiamen University	Breast Cancer, Sentinel Lymph Node	12/24	12/24
Chen, Weiling
NIR, NCT05708144: Fluorescent Molecular Probe for the Identification of Breast Tissue	Completed	N/A	26	RoW	ICG-SG incubation solution	Xiang'an Hospital of Xiamen University	Breast Cancer	10/23	10/23
NIR-II, NCT06713161: Tumor-Targeted- Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status	Recruiting	N/A	40	RoW	NIR-II Probe(i.e ICG-POL6326) incubation solution	Yunnan Cancer Hospital, Xiang'an Hospital of Xiamen University	Breast Cancer, Sentinel Lymph Node, Metastases, Margin Assessment	08/25	12/25